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Background: Ivacaftor is a CFTR potentiator approved for use in CF patients
6 years of age with the G551D gating mutation. This study evaluated the safety
and efﬁcacy of ivacaftor treatment in patients with CF who were 6 years old, had
a non-G551D Class III gating mutation on at least one allele, and an FEV1 >40%
of predicted at screening.
Methods: This two-part, Phase 3 study consisted of a randomized, placebo-
controlled, double-blind, 8-week crossover period and a 16-week open-label ex-
tension period (OLE). Thirty-nine patients were screened and randomized to one
of two treatment sequences including 8 weeks of ivacaftor treatment and 8 weeks
of placebo. The primary outcome measure was the absolute change from baseline
in % predicted FEV1 through 8 (Part 1) and 24 weeks (including the 16-week OLE,
Part 2) of treatment. Secondary outcome measures included absolute change from
baseline in BMI at 8 and 24 weeks, and absolute change from baseline in sweat
chloride and CFQ-R through 8 and 24 weeks.
Results: In Part 1, in the intention-to-treat full analysis set, patients receiving
ivacaftor for 8 weeks had signiﬁcant improvements in % predicted FEV1, BMI,
and sweat chloride (all P < 0.0001) and pooled CFQ-R domain score (P = 0.0004),
compared with placebo. Results from Part 2 will be available for presentation.
Conclusions: Eight weeks of ivacaftor treatment provided clinically relevant and
statistically signiﬁcant improvements compared with placebo in lung function, BMI,
sweat chloride, and CFQ-R in patients with CF and a non-G551D gating mutation,
consistent with the G551D gating trials. Data from Part 2 of this study will address
the durability of these results from Part 1.
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Objectives: Vardenaﬁl, a clinically approved cGMP-dependent phosphodiesterase
type 5 inhibitor (PDE5i), normalizes defective F508del-CFTR chloride transport
across the nasal mucosa of mice carrying the F508del mutation (CF). This work
aimed at evaluating the inﬂuence of vardenaﬁl on CFTR expression and localization
in mouse lungs and in human bronchial epithelial cells in culture.
Methods: CFTR localization was studied by immunohistostaining and evaluated by
a normalized ratio of speciﬁc ﬂuorescence (CFTR antibody clone 24-1) between the
apical and the subapical compartments of cells. Incubation of slides with Pontamine
Sky Blue was performed during 10 minutes before immunostaining to overcome
lung tissue autoﬂuorescence.
Results: Immunohistostaining studies showed reduced CFTR expression in apical
compartments of CF airways: in untreated conditions, the apical/subapical ﬂu-
orescence ratio was lower in CF (1.48±0.09) than in WT tissues (2.24±0.12;
p< 0.0001). In CF tissues, vardenaﬁl treatment increased both the ratio of ﬂuo-
rescence and the peak intensity of the CFTR signal to WT values.
Conclusion: These data show that vardenaﬁl acts as a CFTR corrector by promoting
CFTR relocalization of the protein towards and into the apical compartment where
the wild-type protein is mainly expressed. This work provides compelling support
for studying cGMP pathway as therapeutic strategies in CF pharmacotherapy.
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Objectives: The most common CF causative mutation in CFTR is the deletion
of phenylalanine 508 (F508del), resulting in a rapidly degraded protein that fails
to progress out of the ER and trafﬁc to the cell surface. Multiple strategies to
correct F508del mutant CFTR with small molecules have been employed. For
example, pharmacological chaperones directly bind to and improve the mutant
protein’s folding stability, while protein homeostasis regulators modulate the cellular
folding environment to promote folding, trafﬁcking, and maturation of the mutant
protein. Proteostasis Therapeutics, Inc. (PTI) is pursuing regulators of the protein
homeostasis network (PN) that improve the folding, trafﬁcking, and function of
F508del CFTR.
Methods:We performed a high-throughput screen of small molecules that modulate
PN pathways using our Multiplex Gene Expression platform. Hit compounds were
tested for correction of F508del CFTR using electrophysiology-based assays in
primary human bronchial epithelial lung cells.
Results:Multiple active chemical series were found. PTI Corrector Series B showed
particularly robust activity and has undergone further characterization. Series B
demonstrates substantial correction in combination with a potentiator. Combination
of Series B with known correctors plus a potentiator more than doubles the F508del
CFTR functional rescue of these agents.
Conclusion: Series B has good drug-like physicochemical and ADME properties,
providing a strong foundation for our drug discovery efforts to develop clinically
efﬁcacious CF therapeutics.
Funded in part by a Therapeutics Development Award from Cystic Fibrosis
Foundation Therapeutics, Inc.
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Gene therapy (GT) can treat CF in a curative, mutation independent manner. In this
study, we aim to develop a GT-based mouse model for CF using rAAV2/5 viral
vectors, which efﬁciently transduce airway epithelium. As transduction of dividing
airway epithelium with a non-integrating vector requires repeat administration for
long-term correction, we hypothesized that immune system immaturity during
perinatal GT would prevent an immune response against the vector, allowing repeat
administration.
We administered rAAV2/5-fLUC (luciferase) to the fetal and neonatal mouse
airways which resulted in a comparable fLUC signal in the lungs. However,
fLUC activity decreased 5-fold at 3mo. As only low to absent neutralizing
antibodies (nAb) against the vector were present, this allowed readministration
at 3mo resulting in stable gene expression till 6mo. To replace reporter genes
by CFTR, we had to overcome the size limit of rAAV (~5 kb). Therefore, we
functionally validated a truncated CFTR with a deletion in the R-domain (CFTRDR)
described by Ostedgaard et al. Upon forskolin and genistein stimulation, CFTRDR
showed a 125I− efﬂux comparable to WT CFTR in stable HeLa cell lines. After
in house production, vector titers were obtained comparable to control vectors.
Additionally, rAAV2/5-CFTRDR was functional on the mRNA level measured by
qPCR in transduced 293T cells.
In conclusion, we obtained long-term gene expression in the mouse airways
after perinatal rAAV2/5 administration and readministration using reporter genes.
Currently, we are investigating perinatal rAAV2/5 administration in CF mice to
assess CFTR expression and function by nasal potential difference measurements.
